Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists · 2008
Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Duff Kevin, Beglinger Leigh J, O'Rourke Margaret E, Nopoulos Peg, Paulson Henry L, Paulsen Jane S
Аннотация
BACKGROUND: Huntington's disease (HD) is a progressive, neuropsychiatric disorder, and limited reports indicate that risperidone might improve motor and psychiatric functioning for these patients.
METHODS: In a retrospective, chart review study to evaluate the effectiveness of risperidone on motor, psychiatric, and cognitive functioning in HD, 17 patients taking risperidone in the course of clinical care and 12 patients not taking any antipsychotic medication were compared across a year.
RESULTS: Patients taking risperidone demonstrated significantly improved psychiatric functioning and motor stabilization, whereas patients not taking risperidone were stable psychiatrically and worsened motorically.
CONCLUSIONS: Although controlled clinical trials are clearly needed, these preliminary results support the use of risperidone in patients with HD in treating their psychiatric and possibly motor symptoms.
METHODS: In a retrospective, chart review study to evaluate the effectiveness of risperidone on motor, psychiatric, and cognitive functioning in HD, 17 patients taking risperidone in the course of clinical care and 12 patients not taking any antipsychotic medication were compared across a year.
RESULTS: Patients taking risperidone demonstrated significantly improved psychiatric functioning and motor stabilization, whereas patients not taking risperidone were stable psychiatrically and worsened motorically.
CONCLUSIONS: Although controlled clinical trials are clearly needed, these preliminary results support the use of risperidone in patients with HD in treating their psychiatric and possibly motor symptoms.